Recently presented 15 minute talk on how to recognize a trustworthy practice #guidelines focused on an audience of folks interested in #nutrition. #EBM #Medicine vimeo.com/1069984025?sha…

🆕Excited that our FKSI-23 measure, designed to assess HRQOL in patients with localized and advanced RCC, is available on the FACIT website: facit.org/measures/fksi-… Tom Powles Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Sarah P. Psutka MD MS Brian Rini, MD Elizabeth Plimack MD Viraj Master Viktor Grünwald Laurence Albiges

Powerful message from Prof Rob Jones. A must for all oncologists treating #BladderCancer in the UK, particularly for trainees. Treatment strategies are evolving and we need to remember: “treat the patient, not the service”.

🗣️ Another milestone in non-muscle invasive bladder cancer research 🎗️ Adding 1 year of durvalumab to the standard intravesical BCG impacts in longer Disease Free Survival, the primary endpoint of the phase 3 pivotal #POTOMAC trial. Together with sasanlimab we have a new systemic

Interesting #BladderCancer meeting. Looking forward to this debate. Look at the agenda (picture). Representation from different countries across Europe, America, and Asia. Happy to meet the one and inly only Prof Enrique Grande .

After years of limited options, #BladderCancer SACT is finally evolving. It’s rewarding to hear from those who have been treating BC for many years, like Prof Rob Jones. Glad John McGrane mentioned our work on disparities & drug access for bladder cancer. Many thanks, John!

BREAKING from China HER2+ #BladderCancer may have a new contender! DV (Disitamab Vedotin) + Toripalimab ✅ Met BOTH primary endpoints: • OS • PFS ✅ Statistically significant ✅ Clinically meaningful benefit ✅ Works across HER2 levels (IHC 1+, 2+, 3+) ✅ Safe in

The first bladder transplantation. Amazing surgery just like the first penile transplants and hand. Tho hopefully less controversial nytimes.com/2025/05/18/hea…

Congrats to my friends and massive Spurs fans Ricky Frazer and 𝕨𝕚𝕝𝕝 𝕚𝕟𝕔𝕖 ! #ToDareIsToDo Goal from Brennan Johnson, a 🏴󠁧󠁢󠁷󠁬󠁳󠁿 footballer.

Top oncologists to follow for GU cancer updates during the ASCO 2025. Discover more about #ASCO25: t.ly/7TCD6 #LARVOL #GUCancer #GenitourinaryCancer #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights | Toni Choueiri, MD | Andrea Necchi | Jose C. Tapia |

🚨May is Bladder Cancer awareness month🚨 What better way to recognise this than a Simply Oncology episode with the irrepressible 💙alison birtle 🎙️We discuss peri-operative treatment and the NIAGRA trial 🎙️There is so much happening in #BladderCancer Jose C. Tapia ActionBladderCancer

Really enjoyed the podcast! I was also thrilled by the Twitter post on Thursday and the episode release on Friday. Patients should have access to all available options on the table, regardless of oncologist preference. That’s why these podcasts are so important.

Top #GUCancer Oncologists from ASCO 2025. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #GenitourinaryCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Toni Choueiri, MD | Neeraj Agarwal, MD, FASCO | Andrea Necchi | Tom Powles |

Despite all the scroll-storm in X’s feed, it remains a valuable platform for networking & scientific discussion in oncology - especially, for “new kids on the block” like myself. I’ll keep sharing my conference highlights. Thanks for including me in this list LARVOL #ASCO25

Back to Times square. Celebrating oncologists. OncoAlert OncoDaily Dr Amol Akhade Shaheerr #ASCO25. Tag the top oncologists you recognize. Including rising stars and women oncologists on X.

Recognizing the Rising Stars from ASCO 2025 at Times Square. This list is based on early-career oncologists with high posting volume and the highest increase in views on X. Nicholas Hornstein | Diego A. Díaz García | Roberto Borea, MD | Jose C. Tapia | Oriol Mirallas MD | Michael Serzan, MD | Charles Jiang MD, MPH |

Oh The Lancet, when will you finally let go of this bad habit? If the side effects are “manageable,” then why were there 12 treatment-related Grade 5 toxicities?! Terminology must be used accurately and responsibly!

An excellent review on optimising treatment of stage 2 seminoma. Very well written highlighting the double edge sword - efficacy and toxicity. doi.org/10.1200/OP-25-… Toni Choueiri, MD UroToday.com Jonathan Rosenberg MD Bradley McGregor Karine Tawagi MD Rana McKay, MD, FASCO Matt Galsky Bhardwaj Lab

Are we ready for ARPI alone therapy in mCSPC? Is a non-inferiority trial needed? Great lecture by tombal at #UROonco25 in Sevilla but the debate is still open... European Association of Urology (EAU) European Urology OncoDaily OncoAlert UroFocus Alessandro Volpe Morgan Roupret

Interesting. In the context of 🌍clinical trials and differences in 💊 approvals and reimbursements, non-proportional hazards could be anticipated. Hopefully, we will see more sensitivity analysis regarding subsequent treatments and their impact in survival outcomes.